Hasil Pencarian - Tyler Beardslee

  • Menampilkan 1 - 3 hasil dari 3
Perbaiki Hasil
  1. 1
    Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event

    Switching to an alternative ALK-inhibitor after alectinib-induced pneumonitis resulted in resolution of this adverse event oleh Evan Bryson, Suresh Ramalingam, Tyler Beardslee

    Diterbitkan 2020-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

    Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study oleh Shuhua Wang, Suresh Ramalingam, Sagar Lonial, Walter Curran, Edmund K Waller, Bassel Nazha, Taofeek K Owonikoko, Conor Steuer, Suchita Pakkala, Kristin Higgins, Zhengjia Chen, Gabriel Sica, Guojing Zhang, Mohammad S Hossain, Tyler Beardslee, Fadlo R Khuri

    Diterbitkan 2020-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

    Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report oleh Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: